← back to search

Steven A. Yukl

San Francisco VA Medical Center · US
Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, and HIV-related health complications and treatments.
h-index
31
citations
4,368
works
79
NIH funding
primary concept
email

Recent publications

Correlates of HIV-1 control after combination immunotherapy
Nature 2025cited by 21position: middledoi
Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control
Journal of Virology 2022cited by 19position: lastdoi
Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART
PLoS Pathogens 2021cited by 51position: middledoi
Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response
The Journal of Infectious Diseases 2021cited by 29position: middledoi
Tissue‐specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART‐treated women
Journal of the International AIDS Society 2021cited by 28position: lastdoi
Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir
eLife 2020cited by 93position: middledoi
HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo
Proceedings of the National Academy of Sciences 2020cited by 40position: middledoi
Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 <sup>+</sup> and Gut CD4 <sup>+</sup> T Cells
Journal of Virology 2020cited by 11position: firstdoi
Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency
Retrovirology 2019cited by 65position: lastdoi
Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency
PLoS Pathogens 2018cited by 110position: lastdoi
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study
PLoS Medicine 2017cited by 219position: middledoi
Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation
Nature Medicine 2016cited by 102position: middledoi
CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells
PLoS ONE 2014cited by 107position: middledoi
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
PLoS Pathogens 2013cited by 576position: middledoi
Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient
PLoS Pathogens 2013cited by 290position: firstdoi
The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence
The Journal of Infectious Diseases 2013cited by 181position: firstdoi
Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers
PLoS Pathogens 2013cited by 98position: middledoi
A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells
AIDS 2013cited by 69position: firstdoi
Discordance Between Peripheral and Colonic Markers of Inflammation During Suppressive ART
JAIDS Journal of Acquired Immune Deficiency Syndromes 2013cited by 31position: middledoi
Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo
Proceedings of the National Academy of Sciences 2012cited by 118position: middledoi

Grants

Understanding and targeting the HIV-expressing reservoir to reduce immune activation
NIH1R01AI183666-01$834,9372024–2029Contact PIRePORTER
Understanding and targeting the HIV-expressing reservoir to reduce immune activation
NIH5R01AI183666-03$819,7842024–2029Contact PIRePORTER
Understanding and targeting the HIV-expressing reservoir to reduce immune activation
NIH5R01AI183666-02$795,0832024–2029Contact PIRePORTER
Project-004
NIH5P01AI169606-04$532,3072022–2027Contact PIRePORTER
In situ and digital spatial profiling of the active HIV reservoir in autopsy-derived tissues
NIH5P01AI169606-02$497,1452022–2027Contact PIRePORTER
In situ and digital spatial profiling of the active HIV reservoir in autopsy-derived tissues
NIH1P01AI169606-01$405,2052022–2027Contact PIRePORTER
Core-001
NIH5P01AI169606-03$164,1212022–2027Contact PIRePORTER
Admin-Core-001
NIH5P01AI169606-05$114,7582022–2027Contact PIRePORTER
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes
NIH1R01DK120387-01A1$836,7102019–2024Contact PIRePORTER
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes
NIH5R01DK120387-05$810,3392019–2026Contact PIRePORTER
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes
NIH5R01DK120387-04$810,3392019–2024Contact PIRePORTER
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes
NIH5R01DK120387-03$810,3392019–2024Contact PIRePORTER
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodes
NIH5R01DK120387-02$810,3392019–2024Contact PIRePORTER
Understanding HIV latency reversal and clearance of infected cells in vivo
NIH5R01AI132128-05$383,2502017–2024Contact PIRePORTER
Understanding HIV latency reversal and clearance of infected cells in vivo
NIH5R01AI132128-04$383,2502017–2022Contact PIRePORTER
Understanding HIV latency reversal and clearance of infected cells in vivo
NIH5R01AI132128-03$383,2502017–2022Contact PIRePORTER
Understanding HIV latency reversal and clearance of infected cells in vivo
NIH5R01AI132128-02$383,2502017–2022Contact PIRePORTER
Investigating Mechanisms of HIV Persistence in the Gut
NIH5R01DK108349-05$449,9942015–2021Contact PIRePORTER
Investigating Mechanisms of HIV Persistence in the Gut
NIH5R01DK108349-04$449,9942015–2020Contact PIRePORTER

Frequent collaborators

Steven G. Deeks · University of California, San Francisco12 papers (2013–2022)Joseph K. Wong · Temple College11 papers (2013–2022)Peter W. Hunt · University of California, San Francisco9 papers (2013–2021)Ma Somsouk · University of California, San Francisco8 papers (2013–2021)Peggy Kim · San Francisco VA Medical Center6 papers (2016–2021)Sushama Telwatte · San Francisco VA Medical Center5 papers (2018–2022)Elizabeth Sinclair · Wellcome Sanger Institute4 papers (2013–2014)Jeffrey M. Milush · University of California, San Francisco4 papers (2018–2021)Hiroyu Hatano · University of California, San Francisco4 papers (2013–2021)Rebecca Hoh · World Wide Web Consortium4 papers (2013–2021)Frederick Hecht · University of California, San Francisco4 papers (2013–2022)Robert F. Siliciano · University of Baltimore4 papers (2013–2020)Sarah Palmer · The University of Sydney4 papers (2013–2020)Jeffrey N. Martin · Global Solutions for Infectious Diseases3 papers (2013–2021)Janet D. Siliciano · Howard Hughes Medical Institute3 papers (2013–2020)Diane V. Havlir · Global Solutions for Infectious Diseases3 papers (2013–2016)Warner C. Greene · Gladstone Institutes3 papers (2016–2020)Mohamed Abdel‐Mohsen · The Wistar Institute3 papers (2013–2021)Joseph M. McCune · Gates Foundation3 papers (2013–2021)Nadia R. Roan · Gladstone Institutes3 papers (2020–2021)